Lantheus’ TAUKLARIFY PET imaging meets key endpoints in two Phase 3 Alzheimer’s studies
LNTH•Lantheus said two Phase 3 studies of TAUKLARIFY PET imaging met their primary diagnostic goals for detecting Alzheimer’s-related tau pathology. Results showed consistent performance across independent readers, and a pooled safety analysis found the imaging agent generally well tolerated.




